346 related articles for article (PubMed ID: 32967334)
1. Current Understanding of the Relationship of HDL Composition, Structure and Function to Their Cardioprotective Properties in Chronic Kidney Disease.
Marsche G; Heine GH; Stadler JT; Holzer M
Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32967334
[TBL] [Abstract][Full Text] [Related]
2. Apolipoprotein B, Triglyceride-Rich Lipoproteins, and Risk of Cardiovascular Events in Persons with CKD.
Lamprea-Montealegre JA; Staplin N; Herrington WG; Haynes R; Emberson J; Baigent C; de Boer IH;
Clin J Am Soc Nephrol; 2020 Jan; 15(1):47-60. PubMed ID: 31831577
[TBL] [Abstract][Full Text] [Related]
3. Association of cholesterol efflux capacity with plasmalogen levels of high-density lipoprotein: A cross-sectional study in chronic kidney disease patients.
Maeba R; Kojima KI; Nagura M; Komori A; Nishimukai M; Okazaki T; Uchida S
Atherosclerosis; 2018 Mar; 270():102-109. PubMed ID: 29407877
[TBL] [Abstract][Full Text] [Related]
4. Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density Lipoprotein.
Kon V; Yang H; Fazio S
Arch Med Res; 2015 Jul; 46(5):379-91. PubMed ID: 26009251
[TBL] [Abstract][Full Text] [Related]
5. Importance of high-density lipoprotein quality: evidence from chronic kidney disease.
Kon V; Ikizler TA; Fazio S
Curr Opin Nephrol Hypertens; 2013 May; 22(3):259-65. PubMed ID: 23470818
[TBL] [Abstract][Full Text] [Related]
6. HDL in CKD-The Devil Is in the Detail.
Kronenberg F
J Am Soc Nephrol; 2018 May; 29(5):1356-1371. PubMed ID: 29472417
[TBL] [Abstract][Full Text] [Related]
7. Impaired Renal Function on Cholesterol Efflux Capacity, HDL Particle Number, and Cardiovascular Events.
Chindhy S; Joshi P; Khera A; Ayers CR; Hedayati SS; Rohatgi A
J Am Coll Cardiol; 2018 Aug; 72(6):698-700. PubMed ID: 30072004
[No Abstract] [Full Text] [Related]
8. Dysfunctional high-density lipoproteins in children with chronic kidney disease.
Kaseda R; Jabs K; Hunley TE; Jones D; Bian A; Allen RM; Vickers KC; Yancey PG; Linton MF; Fazio S; Kon V
Metabolism; 2015 Feb; 64(2):263-73. PubMed ID: 25467845
[TBL] [Abstract][Full Text] [Related]
9. From High-Density Lipoprotein Cholesterol to Measurements of Function: Prospects for the Development of Tests for High-Density Lipoprotein Functionality in Cardiovascular Disease.
Sacks FM; Jensen MK
Arterioscler Thromb Vasc Biol; 2018 Mar; 38(3):487-499. PubMed ID: 29371248
[TBL] [Abstract][Full Text] [Related]
10. The Role and Function of HDL in Patients with Chronic Kidney Disease and the Risk of Cardiovascular Disease.
Rysz J; Gluba-Brzózka A; Rysz-Górzyńska M; Franczyk B
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963445
[TBL] [Abstract][Full Text] [Related]
11. Role of HDL function and LDL atherogenicity on cardiovascular risk: A comprehensive examination.
Hernáez Á; Soria-Florido MT; Schröder H; Ros E; Pintó X; Estruch R; Salas-Salvadó J; Corella D; Arós F; Serra-Majem L; Martínez-González MÁ; Fiol M; Lapetra J; Elosua R; Lamuela-Raventós RM; Fitó M
PLoS One; 2019; 14(6):e0218533. PubMed ID: 31246976
[TBL] [Abstract][Full Text] [Related]
12. Inflammation Alters Relationship Between High-Density Lipoprotein Cholesterol and Cardiovascular Risk in Patients With Chronic Kidney Disease: Results From KNOW-CKD.
Kim JY; Park JT; Kim HW; Chang TI; Kang EW; Ahn C; Oh KH; Lee J; Chung W; Kim YS; Kim SW; Yoo TH; Kang SW; Han SH;
J Am Heart Assoc; 2021 Aug; 10(16):e021731. PubMed ID: 34369187
[TBL] [Abstract][Full Text] [Related]
13. Lipotoxicity and impaired high density lipoprotein-mediated reverse cholesterol transport in chronic kidney disease.
Vaziri ND
J Ren Nutr; 2010 Sep; 20(5 Suppl):S35-43. PubMed ID: 20797569
[TBL] [Abstract][Full Text] [Related]
14. High-Density Lipoprotein Subfractions and Their Oxidized Subfraction Particles in Patients with Chronic Kidney Disease.
Honda H; Hirano T; Ueda M; Kojima S; Mashiba S; Hayase Y; Michihata T; Shibata T
J Atheroscler Thromb; 2016; 23(1):81-94. PubMed ID: 26289085
[TBL] [Abstract][Full Text] [Related]
15. Plasma metabolite profiles, cellular cholesterol efflux, and non-traditional cardiovascular risk in patients with CKD.
Ganda A; Yvan-Charvet L; Zhang Y; Lai EJ; Regunathan-Shenk R; Hussain FN; Avasare R; Chakraborty B; Febus AJ; Vernocchi L; Lantigua R; Wang Y; Shi X; Hsieh J; Murphy AJ; Wang N; Bijl N; Gordon KM; de Miguel MH; Singer JR; Hogan J; Cremers S; Magnusson M; Melander O; Gerszten RE; Tall AR
J Mol Cell Cardiol; 2017 Nov; 112():114-122. PubMed ID: 28478047
[TBL] [Abstract][Full Text] [Related]
16. Lower Apo A-I and lower HDL-C levels are associated with higher intermediate CD14++CD16+ monocyte counts that predict cardiovascular events in chronic kidney disease.
Rogacev KS; Zawada AM; Emrich I; Seiler S; Böhm M; Fliser D; Woollard KJ; Heine GH
Arterioscler Thromb Vasc Biol; 2014 Sep; 34(9):2120-7. PubMed ID: 25060791
[TBL] [Abstract][Full Text] [Related]
17. There is a U shaped association between non high density lipoprotein cholesterol with overall and cardiovascular mortality in chronic kidney disease stage 3-5.
Chiu H; Wu PY; Huang JC; Tu HP; Lin MY; Chen SC; Chang JM
Sci Rep; 2020 Jul; 10(1):12749. PubMed ID: 32728174
[TBL] [Abstract][Full Text] [Related]
18. The rationale for using apoA-I as a clinical marker of cardiovascular risk.
Barter PJ; Rye KA
J Intern Med; 2006 May; 259(5):447-54. PubMed ID: 16629850
[TBL] [Abstract][Full Text] [Related]
19. Kidney function is associated with an altered protein composition of high-density lipoprotein.
Rubinow KB; Henderson CM; Robinson-Cohen C; Himmelfarb J; de Boer IH; Vaisar T; Kestenbaum B; Hoofnagle AN
Kidney Int; 2017 Dec; 92(6):1526-1535. PubMed ID: 28754556
[TBL] [Abstract][Full Text] [Related]
20. High-density Lipoprotein (HDL) Dysfunction and the Future of HDL.
Ertek S
Curr Vasc Pharmacol; 2018; 16(5):490-498. PubMed ID: 29149817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
